Capricor Therapeutics Hits New 52-Week Low at $4.40 Amid Financial Struggles

Capricor Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 4.40 as of November 24, 2025. This decline marks a significant downturn for the stock, which has experienced a 14.23% decrease over the past year, contrasting sharply with the S&P 500's performance of 11.0% during the same period.
The company's financial metrics reveal ongoing challenges, with net sales for the first nine months of the year reported at USD 11.13 million, reflecting a substantial decline of 46.91%. Additionally, Capricor's operating cash flow has reached a low of USD -52.99 million, indicating financial strain. The rising cost of raw materials, which has increased by 101.11% year-over-year, further complicates the company's financial landscape.

With a market capitalization of USD 290 million, Capricor's price-to-book ratio stands at 2.77, while it continues to grapple with negative returns on equity of -66.66%. The stock's performance over the past year has been notably poor, generating returns of -67.68%, underscoring the challenges faced by the company in both the short and long term.